Cargando...

A Phase I study of Sirolimus and Bevacizumab in Patients with Advanced Malignancies

BACKGROUND: We performed a single institution, phase I study of sirolimus and bevacizumab, in order to determine the dose limiting toxicity (DLT) and recommended phase II doses. PATIENTS AND METHODS: Eligible patients had previously treated advanced malignancies and were enrolled in three cohorts. S...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cohen, E.E.W., Sharma, M.R., Janisch, L., Llobrera, M., House, L., Wu, K., Ramirez, J., Fleming, G.F., Stadler, W.M., Ratain, M.J.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4116678/
https://ncbi.nlm.nih.gov/pubmed/21439817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2011.02.017
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!